Skip to content

Investigating the efficacy of cold therapy in improving the symptoms of migraine attacks

Investigating the efficacy of cold therapy in improving the symptoms of migraine attacks in patients referred to Imam Reza Clinic of Shiraz University of Medical Sciences a randomized controlled clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20260424069148N1
Enrollment
62
Registered
2026-05-06
Start date
2026-05-22
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine. Migraine with aura

Interventions

Intervention 1: Intervention group: Intervention group: Use of a freezable gel-equipped cap kept in the freezer, placed on the patient's head and eyes for 25 minutes at the onset of a migraine attack.

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of migraine by a neurologist based on ICHD criteria with or without aura Age 18 years and older History of migraine for at least 6 months Willingness and informed consent to participate in the study

Exclusion criteria

Exclusion criteria: Patient's lack of consent to participate in the study Concurrent presence of other primary or secondary headache types such as dominant tension headache or cluster headache Menstrual migraine History of medication overuse headache, especially ergotamine Presence of severe neurological or systemic diseases that can affect headache evaluation Presence of diseases or conditions that prevent the use of cold therapy, such as severe sensitivity to cold, skin diseases in the head area, or cold-related vascular disorders Suffering from serious eye diseases including glaucoma and recent major eye surgery Pregnancy or lactation at the discretion of the researcher

Design outcomes

Primary

MeasureTime frame
Headache severity in migraine attacks. Timepoint: At the beginning of the study (before starting the intervention) and one month after starting the intervention. Method of measurement: Visual Analogue Scale (VAS).

Secondary

MeasureTime frame
Severity of nausea and vomiting associated with migraine attacks. Timepoint: At the beginning of the study (before starting the intervention) and one month after starting the intervention. Method of measurement: Visual Analogue Scale (VAS).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarzieh Salimi

Shiraz University of Medical Sciences

salimi.md67@gmail.com+98 71 3212 7000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026